East Windsor, NJ—Sabinsa has obtained Novel Food approval from the European Food Safety Authority (EFSA) for its patented Curcumin C3 Reduct, which contains the curcuminoid metabolites Tetrahydrocurcuminoids (THCs). Once a novel food is authorized and added to the list, it may be sold throughout the EU, the press release says.

Several studies support the benefits of THCs, the press release says, with research showing specifically that C3 Reduct is an antioxidant equal or superior to curcumin. There is also research backing the impact of THCs on colonic health, and backing the anti-inflammatory effects of THCs.

Related: Sabinsa Founder Named Father of Indian Nutraceuticals Industry Curcumin Complex Studied in COVID-19 Patients Study Supports Curcumin Metabolites for Oral Health

“Gut resident bacteria also metabolize curcumin to THC, thus explaining many of the benefits that are ascribable to curcuminoids,” said Dr. Muhammed Majeed, Founder and Chairman of Sami-Sabinsa Group. “The benefits are comprehensively described in a recent monograph Sabinsa has published. Incidentally C3 Reduct is a fitting solution to the perceived limited systemic bioavailability of curcumin. I commend our technical and commercial teams that worked hard to reach this milestone.”